Lowering Blood Pressure Curing the Kidneys ~

Why invest in Curespec?

Strong Cash Flow Generation in the Cash Medicine Market
Curespec operates in a growing sector, benefiting from high demand for non-invasive medical technologies. Nephrospec, a breakthrough kidney treatment, is well-positioned to capture a significant share of the cash medicine market.

Proven Track Record
Curespec has a strong history of developing and successfully commercializing shockwave technology. The company has proven its ability to scale and generate revenue, establishing a solid foundation for future growth.

Expected Future Cash Flow Growth
With a unique, innovative solution like Nephrospec, Curespec is poised to experience significant growth. The expected expansion into global markets, coupled with strong demand, presents an exciting opportunity for investors.

GO-TO-Market Strategy

Curespec is marketing Nephrospec to hospitals and clinics across Europe, leveraging its CE approval. The next phase of expansion will target the USA, following FDA approval and the establishment of reimbursement codes. Together, Europe and the USA represent nearly 1.7 million potential patients annually for Nephrospec.

This opens up a market opportunity of over $15 billion annually.